Form 4: Nurix CFO Sells Shares for Tax Obligations

Nurix Therapeutics' CFO, Hans van Houte, reported the acquisition of common stock through RSU vesting and subsequent sales to cover tax withholding obligations.

Summary

• Hans van Houte, Chief Financial Officer of Nurix Therapeutics, Inc. (NRIX), reported transactions on January 30, 2026.
• Acquired a total of 11,496 shares of common stock through the vesting of Restricted Stock Units (RSUs) at an exercise price of $0.
• Disposed of 3,661 shares of common stock in 'sell to cover' transactions to satisfy tax withholding obligations.
• The sales occurred at weighted average prices of $16.5826 for 3,588 shares (ranging from $16.33 to $17.32) and $17.3717 for 73 shares (ranging from $17.33 to $17.49).
• Following these transactions, Hans van Houte beneficially owns 45,427 shares of Nurix Therapeutics, Inc. common stock.
• The RSU vesting schedules vary, with some vesting quarterly over four years starting April 30, 2022, and others vesting 1/12 quarterly over three years starting July 30, 2023, July 30, 2024, and July 30, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions are routine 'sell to cover' sales for tax purposes, which are common for executives receiving equity compensation and do not reflect a discretionary decision regarding the company's prospects.

Positives

• The CFO received a significant number of shares (11,496) through RSU vesting, indicating ongoing equity compensation as part of their remuneration package.

Negatives

• The reported sales were mandatory 'sell to cover' transactions for tax purposes, not discretionary sales, and therefore do not reflect a lack of confidence in the company by the reporting person.

Future Outlook

The filing indicates ongoing RSU vesting for the CFO according to pre-determined schedules, suggesting continued equity compensation as part of the executive's remuneration.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and routine mechanism for executives to manage tax obligations arising from the vesting of equity awards, such as Restricted Stock Units. These transactions are typically pre-arranged and not indicative of a discretionary decision to sell company stock.

Stakeholder Impact

• Minimal impact on shareholders as these are routine, non-discretionary transactions by an insider to cover tax obligations.
• For the CFO, the vesting represents a realization of equity compensation, which is a standard component of executive pay.

Next Steps

• Continued vesting of the remaining Restricted Stock Units for Hans van Houte according to their respective schedules.

Key Dates

Recommendation

This Form 4 reports routine insider transactions related to equity compensation and tax obligations. It does not provide new information about the company's financial performance, strategic direction, or operational health that would warrant a change in investment recommendation. The 'sell to cover' sales are not discretionary and therefore do not signal a lack of confidence from the CFO.

Keywords

NRIX, Nurix Therapeutics, Form 4, insider trading, RSU, stock sale, CFO, equity compensation